Does LORLATINIB Cause Malignant neoplasm progression? 130 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 130 reports of Malignant neoplasm progression have been filed in association with LORLATINIB (Lorbrena). This represents 2.4% of all adverse event reports for LORLATINIB.
130
Reports of Malignant neoplasm progression with LORLATINIB
2.4%
of all LORLATINIB reports
24
Deaths
23
Hospitalizations
How Dangerous Is Malignant neoplasm progression From LORLATINIB?
Of the 130 reports, 24 (18.5%) resulted in death, 23 (17.7%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LORLATINIB. However, 130 reports have been filed with the FAERS database.
What Other Side Effects Does LORLATINIB Cause?
Death (1,050)
Neoplasm progression (633)
Off label use (394)
Weight increased (306)
Hallucination (290)
Blood cholesterol increased (281)
Dyspnoea (223)
Oedema peripheral (198)
Oedema (195)
Fatigue (188)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which LORLATINIB Alternatives Have Lower Malignant neoplasm progression Risk?
LORLATINIB vs LORMETAZEPAM
LORLATINIB vs LORNOXICAM
LORLATINIB vs LOSARTAN
LORLATINIB vs LOSARTAN\LOSARTAN
LORLATINIB vs LOTEPREDNOL ETABONATE